Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis

Fig. 4

Overall survival according to resection and pathological response. a Overall survival in patients treated with or without radical resection between the DOS and XELOX groups. b Overall survival in responders or non-responders between the DOS and XELOX groups. c Overall survival in patients treated with or without radical resection. d Overall survival in pathological responders or non-responders

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us